Hexarelin
Hexarelin, also called examorelin, is a synthetic hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
The short version
- Why people discuss it
- Discussed for growth-hormone signaling, muscle/recovery goals and sleep. Community interest does not establish benefit or a suitable treatment.
- What it is
- Hexarelin, also called examorelin, is a synthetic hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
- Biggest caution
- Acute endocrine-response studies do not establish muscle gain, recovery or long-term safety. Similarity to other secretagogues does not make their regimens or risk profiles interchangeable.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Legacy community reference: no complete dosing regimen was independently corroborated by the two new source collections.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–200 mcg per administration
- Frequency
- 2–3 times daily
- Duration / phase
- 4–8 weeks
Community pattern with desensitization uncertainty The new inbox sources do not independently corroborate this complete regimen. Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12